PD-173074 is a small molecule inhibitor of fibroblast growth factor receptor 1 (FGFR1) and FGFR3. It was first synthesized by Pfizer in 2000 and has since been studied for its potential as a cancer treatment.
Chemical name:
The chemical name for PD-173074 is N-(2-methyl-5-(3-(4-(pyridin-3-yl)benzyl)-1H-indazol-6-yl)thiazol-4-yl)-N′-(3-(trifluoromethyl)phenyl)urea.
Molecular formula:
The molecular formula of PD-173074 is C27H21F3N6OS.
Formula weight:
The formula weight of PD-173074 is 546.56 g/mol.
CAS No:
The CAS number of PD-173074 is 219580-11-7.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
PD-173074 has been primarily developed for the treatment of cancer. It is a selective inhibitor of FGFR1 and FGFR3, which are overexpressed in many types of cancer cells. By inhibiting these receptors, PD-173074 may help to slow or stop the growth of cancer cells.
Potential effects:
Some potential effects of PD-173074 include:
Product mechanism:
PD-173074 works by inhibiting FGFR1 and FGFR3, which are receptor tyrosine kinases that play an important role in cell growth and differentiation. These receptors are often overexpressed or mutated in cancer cells, leading to their uncontrolled growth and survival. By inhibiting FGFR1 and FGFR3, PD-173074 may help to restore normal cellular signaling and slow or stop the growth of cancer cells.
Safety:
PD-173074 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with PD-173074.
Side effects:
PD-173074 can cause several side effects in some patients. These can include:
Dosing information:
The optimal dosing regimen of PD-173074 has not yet been established and further research is needed to determine the most effective dose. Doses ranged from 20 mg/kg to 80 mg/kg per day in preclinical studies. In clinical trials, doses ranged from 50 mg to 200 mg per day. The drug is typically administered orally.
Conclusion:
PD-173074 is a small molecule inhibitor of FGFR1 and FGFR3 that has shown potential as a treatment for cancer. By inhibiting these receptors, PD-173074 may help to slow or stop the growth of cancer cells by restoring normal cellular signaling. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of PD-173074 in treating cancer
